Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), a once-daily, bactericidal, and intravenous antibiotic with activity against gram-positive organisms, including methicillin-resistant staphylococcus aureus; and ENTEREG, an alvimopan for acceleration of upper and lower gastrointestinal recovery. It also co-promotes DIFICIDTM used for the treatment of clostridium difficile-associated diarrhea in the United States. The company’s clinical development product pipeline consists of CXA-201, which is in the Phase III clinical trial for patients with complicated urinary tract infections and complicated intra-abdominal infections. It is also developing CXA-201 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. In addition, the company’s products under development comprise CB-315, an oral, bactericidal lipopeptide with in vitro bactericidal activity against C. difficile, for the treatment of clostridium difficile-associated diarrhea (CDAD); and CB-5945, an oral, peripherally-restricted mu opioid receptor antagonist for the treatment of chronic OIC, as well as CB-625 for acute pain. Further, its pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. The company also has collaborations and agreements with third parties that are focused on the research and development of acute care products. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.

Key Statistics